pharma · Triple Negative Breast Cancer (TNBC) · Mesothelin-Expressing Tumors · CNTX
Context Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Context Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in Context Therapeutics's portfolio. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
Development asset linked to Context Therapeutics in public FDA and regional records.
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
US regulatory status: approved. Molecular target: Aromatase.
Development asset linked to Context Therapeutics in public FDA and regional records.
Cardiovascular system (C02) compound in Context Therapeutics's portfolio. Molecular target: Endothelin receptor, ET-A/ET-B.